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Deleterious effect of proton pump inhibitors on the 
disease course of cirrhosis
Tamás Jankaa, Tamás  Tornaia, Brigitta Borbélyc, Dávid Tornaib, István Altorjaya, Mária Pappa,* and  
Zsuzsanna Vitálisa,*  
Objectives Proton pump inhibitors(PPIs) are widely prescribed to patients with liver cirrhosis. We hypothesized that long-
standing PPI use is associated with spontaneous bacterial peritonitis(SBP) and accelerated development of disease-specific 
complications and liver-related death.
Methods A 5-year follow-up observational cohort study assessed the impact of long-standing PPI use on the clinical course 
of cirrhosis in a large referral patient cohort. Three hundred fifty patients with cirrhosis (alcohol:69.1%, Child-Pugh stage 
A/B/C:206/108/36) were assigned to two groups: regular PPI users (n=196) and nonusers (n=154). Occurrence of SBP, 
decompensation events (ascites, hepatic encephalopathy and variceal bleeding), and liver-related death were assessed.
Results Regular PPI use was associated with an increased cumulative probability of SBP compared to nonusers [55% 
vs. 24.8%, hazard ratio(HR):4.25; P=0.05], in patients without previous SBP episode (n=84). A similar association was 
found between regular PPI use and decompensation events. The risk of the development of a first decompensation was 
higher in regular PPI users compared with nonusers, in patients with compensated clinical stage at enrollment (HR: 2.81, 
P= 0.008, n=146). The risk of liver-related death was also significantly increased among regular PPI users (P<0.001). In 
multivariate Cox-regression analysis, regular PPI use (HR:2.81, P=0.003) and MELD score (HR:1.21, P<0.001) was an 
independent predictor of mortality.
Conclusion In the present follow-up cohort study, long-term PPI use was associated with the development of SBP and 
a progressive disease course in patients with cirrhosis that may have been caused by enhanced pathologic bacterial 
translocation, accelerated development of bacterial translocation-dependent disease-specific complications, and liver-related 
death. Eur J Gastroenterol Hepatol XXX: 00–00
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
Introduction
The recent identification of specific pathophysiological 
processes in cirrhosis shows the importance of the possibil-
ity of bacterial infections in the prognosis of the disease [1]. 
Bacterial infections are common causes of morbidity and 
mortality in the cirrhotic patient population. Disruption 
of gut barrier function, small bowel bacterial overgrowth 
(SIBO), dysmotility, and compromised immune defense 
each increase the chances of pathological bacterial trans-
location [2]. Bacteria and bacterial products in the sys-
temic circulation can decompensate hepatic status and 
induce elevation of portal pressure, creating complications 
– including variceal bleeding, hepatic encephalopathy, and 
renal failure – and are responsible for enhanced disease 
progression. Spontaneous bacterial peritonitis (SBP) is the 
most common infection in cirrhosis and has a great prob-
ability of recurrence. Preventive measures are important. 
Prophylactic antibiotic treatment can decrease recurrence 
[3], but it induces bacterial resistance [4]. Novel, nonanti-
biotic-based prophylaxes are highly needed but still in an 
experimental phase.
As proton pump inhibitors (PPIs) are presumed to have 
insignificant side effects, although recent research suggests 
otherwise, they are commonly used without appropriate 
indications [5]. They are highly effective in the treatment 
of peptic ulcer disease, especially in bleeding episodes, 
because the alkaline shift in gastric pH has a beneficial 
effect on the stabilization of blood clot [6,7]. PPIs are also 
widely used in the treatment and prevention of variceal 
bleeding in cirrhosis.
Patients with cirrhosis often prescribed PPIs, even 
though the indication for their use is not always straight-
forward. It is possible that these patients have higher 
incidence of gastroesophageal reflux (GERD), which 
causes symptoms, or that doctors use PPIs for prophy-
lactic reasons. Previous studies postulated that ascites 
accumulation in patients with cirrhosis may result in 
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GERD [8]. Large and endoscopically treated varices 
may alter the esophageal motility and disturb the eso-
phageal sphincter function, which might also provoke 
GERD [9,10]. By damaging the otherwise thin wall of 
varices, acidic irritation may induce their rupture. This 
suggests that GERD might be a provoking factor of 
variceal bleeding and that PPIs may have a prophylac-
tic effect. Despite this promising hypothesis, evidence for 
the protective role of PPIs in variceal bleeding is poor. 
Several clinical trials demonstrated no improvement in 
the risk of portal hypertension-related bleeding with PPI 
treatment [11,12]. Another problem is that although in 
some studies GERD was more common in patients with 
cirrhosis as compared with a healthy population, the low 
sample size of these studies makes their results highly 
questionable [13,14]. Regardless of these uncertainties, 
PPIs are frequently prescribed for patients with cirrhosis. 
This not only increases economic costs in daily clinical 
practice but, according to an increasing body of research, 
can also lead to unfavorable side effects, including oste-
oporosis, pneumonia [15], SIBO, enteric infections, and 
Clostridium difficile colitis [16]. The association of PPI 
use with the occurrence of SBP in cirrhotic patients is 
the most extensively evaluated adverse outcome. Some 
studies found an association [17–21] and some studies 
did not find one [22–24]. Three out of four meta-anal-
yses found an association between PPI use and develop-
ment of SBP [25–27]. A fourth meta-analysis concluded 
that the association has little clinical relevance. Recent 
high-quality studies with a large sample size did not find 
an association [28]. The problem with evaluating these 
studies is that they differ in study design, sample size, 
inclusion criteria, and the inconsistency in specifying the 
exact duration of PPI use.
SBP can be a sign of increased bacterial translocation. 
Previous research has concentrated only on the diagnosis 
of SBP. We hypothesized that long-term PPI use is linked 
to enhanced bacterial translocation-related complications 
in general. If this is right, PPI use would be associated not 
only with SBP but also with enhanced disease progression, 
for example, the appearance of the first decompensation 
event or liver-related death. For this reason, we evaluated 
more general effects of PPIs in patients with decompen-
sated and compensated liver disease.
The aim of the present follow-up observational study 
of PPI use in a large referral patient cohort with cirrhosis 
was to determine if long-term PPI administration consti-
tutes a risk for: (1) SBP; (2) a progressive disease course, 
namely, the advent of decompensation events (devel-
opment of ascites, hepatic encephalopathy, and variceal 
bleeding); and (3) mortality.
Material and methods
Patient population
We conducted a cohort study of 350 adult patients with 
established diagnosis of cirrhosis of different etiologies in 
a referral hepatology center (Division of Gastroenterology, 
Department of Internal Medicine, Clinical Center, 
University of Debrecen, Hungary).
The patients in the study group were a subgroup of 404 
patients with cirrhosis recruited between 1 May 2006 and 
31 December 2010 [29]. We selected 350 patients who 
were stable, that is, had no signs of acute decompensation 
in regular or extraordinary follow-up visits and did not 
meet three exclusion criteria: (1) the patient or legal surro-
gate declined to participate in this study and did not sign 
the informed consent, (2) the patient was sent for a single 
specialist consultation only and was followed up regularly 
elsewhere, or (3) the patient had a follow-up shorter than 
3 months.
Diagnosis of cirrhosis was based on clinical, biochem-
ical, imaging, and, when available, histological data. 
Routine laboratory data and detailed clinical phenotypes 
were captured at inclusion. Clinical data were determined 
by in-depth review of detailed medical records. Age at 
diagnosis, etiology, presence of hepatocellular carcinoma 
(HCC), presence of esophageal varices, history of previ-
ous acute decompensation episodes, and cirrhosis-related 
medication were retrospectively analyzed for the period 
prior to the observational follow-up study. At enrollment 
into the study, disease severity was assessed by liver-ori-
ented scores (Child-Pugh and MELD) and the clinical 
stage of the diseases (compensated/ decompensated) [30] 
were determined.
The data collection, comprising clinical variables and 
outcomes, and also medication was collected prospectively.
Phenotypical characterization of patients during 
follow-up
Attending gastroenterologists registered the date and 
type of acute decompensation episodes during previous 
hospital admissions of the patients in the study. Acute 
decompensation was defined by acute development of 
large ascites (grade II/III), acute hepatic encephalop-
athy, acute variceal bleeding, or presence of systemic 
bacterial infection, including SBP. Diagnosis of SBP was 
based on ascitic fluid polymorphonuclear cell count 
exceeding 250/mm3, with or without positive ascites 
culture, following the AASLD Practice Guidelines of 
2004 [31]. The follow-up period lasted 5  years, or until 
death or loss of follow-up. One hundred forty-seven 
(42%) patients died during follow-up. The median 
time to death was 575 days [interquartile range (IQR): 
286–885]. In the 203 patients alive at the end of the fol-
low-up, the median follow-up lasted 1155 days (IQR: 
646–1741). Collected data were transferred to and 
stored in a database. At the end of the study period, 31 
December 2013, attending gastroenterologists checked 
medical records registered during regular and extraor-
dinary outpatient follow-up visits and inpatient stays to 
identify long-standing PPI use.
The study cohort (N  =  350) was divided into two 
groups: regular PPI users (n  =  196) and nonusers 
(n  =  154). Regular PPI users were defined as taking the 
drug for at least 80% of the follow-up period; nonusers 
were defined as not taking PPI at all during the study. 
Fifty-four of enrolled patients were excluded at the end 
because of episodic or uncertain PPI use. Clinical charac-
teristics of patients at inclusion are presented in Table 1. In 
Hungary, a regular outpatient follow-up visit for patients 
with decompensated cirrhosis is usually scheduled every 3 
months after hospitalization for acute decompensation at 
a specialized gastroenterology center. Follow-ups might be 
scheduled between every 1–3 months if dictated by disease 
severity or the presence of disease-specific complications, 
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and for patients with cirrhosis but without a prior epi-
sode of acute decompensation follow-ups are scheduled 
for every 6 months maximum. This follow-up schedule 
enables reliable tracing of drug-taking habits.
Ethical permission
The study protocol was approved by the Regional and 
Institutional Research Ethics Committee of University 
of Debrecen and the National Scientific and Research 
Ethics Committee (DEOEC-RKEB/IKEB 5306–9/2011, 
3885/2012/EKU [60/PI/2012], 9485-1/2016/EKU ad 
167/2016). Patients were informed of the nature of the 
study and gave written informed consent.
Statistical analysis
Variables were tested for normality using Shapiro Wilk’s 
W test. Continuous variables were summarized as means 
(SD) or as medians (interquartile range [IQR], low-
est 25%–highest 25%) according to their homogene-
ity. Categorical variables were compared with Fisher’s 
exact test or χ2 test with Yates correction, as appropriate. 
Continuous variables were compared with Mann–Whitney 
U test or Kruskal–Wallis H test with Dunn’s multiple com-
parison post-hoc analysis. Paired samples were analyzed 
by Wilcoxon signed-rank test. Kaplan–Meier analysis was 
used to calculate the cumulative probability of adverse 
outcome (SBP, decompensation event, and mortality). 
Differences in observed probabilities were assessed by the 
log-rank test. The association between categorical clinical 
variables or PPI use and adverse disease outcomes during 
follow-up was assessed by univariate Cox-regression anal-
ysis. Multivariate analyses were performed with backward 
elimination procedure and likelihood ratio test to identify 
independent predictors. Associations are given as hazard 
ratio (HR) with 95% confidence intervals (CIs). For sta-
tistical analysis and graphical presentation, the SPSS 22.0 
(SPSS, Chicago, Illinois, USA), and GraphPad Prism 6 (San 
Diego, California, USA) programs were used. A two-sided 
probability value of <0.05 was considered to be statisti-
cally significant.
Results
Study population
Three hundred fifty patients with cirrhosis were enrolled 
in the study. At the time of inclusion, 196 (56.0%) were 
PPI users. The main characteristics of patients are sum-
marized in Table 1. There were 188 men and 162 women, 
with a median age of 56  years (range: 50–64) in our study. 
The main baseline characteristics were as follows: alco-
holic liver disease in 242 out of 350 patients (69.1%). 
One hundred seventy-one patients (48.9%) had extrahe-
patic comorbidities. One hundred thirteen (32.3%) had 
ascites at inclusion, while 100 (28.6%) had prior variceal 
bleeding or 19 (5.4%) had prior hepatic encephalopathy 
episodes. The distribution of Child-Pugh stage was the 
following: 58.9, 30.9, and 10.3% for Child A, B, and C, 
respectively.
Among patients with ascites at inclusion (113) the PPI 
user and nonuser patient groups did not differ in gender, 
age, or presence of comorbidities or HCC, and disease 
stage, as indicated by median values of MELD score, or 
distribution of Child-Pugh stage. (Table 2).
One hundred forty-six patients had compensated clini-
cal stage at the time of inclusion (Table 3). Compensated 
patients had no ascites, variceal bleeding, hepatic encepha-
lopathy, or SBP at inclusion or in their previous history. The 
PPI user and nonuser patient groups did not differ signifi-
cantly in gender, age, alcoholic etiology, presence of comor-
bidities, HCC nor had they advanced disease stage according 
to MELD score, or distribution of Child-Pugh stage.
In patients with compensated disease stage, the primary 
endpoint of the study was the development of the first 
decompensation event (hepatic encephalopathy, variceal 
bleeding, and ascites). In patients with decompensated 
disease stage (patients with ascites), the primary endpoint 
was the development of SBP.
The secondary endpoint was the liver-related death in 
both patient groups.
Risk factors of spontaneous bacterial peritonitis
Of all patients in the study with ascites, 31.9% (36/113) 
developed at least one SBP episode during the follow-up 
period. The median time to the development of first SBP 
episode was 366  days (IQR, 153–969). Prior history of an 
SBP episode [HR: 2.02 (95% CI: 1.03–3.94), P  =  0.04], 
but not age, gender, etiology, or severity of the disease 
were associated with increased risk of SBP development 
(data not shown). PPI use was associated with an increased 
cumulative probability of SBP [55.0% vs. 30%, HR: 2.76 
(95% CI: 1.2–6.31), P  =  0.017]. MELD score did not dif-
fer, however, between two patient groups (median, IQR: 
16 [13–21] for PPI users vs. 14 [11–18] for PPI nonusers, 
P  =  0.06). Further investigation of the association between 
PPI use and increased risk of SBP development showed 
that PPI use increased the risk of SBP development only in 
patients who did not have a previous SBP episode (n  =  84) 
(Fig. 1). In this patient group, the cumulative probability 
of SBP was 55.0% in PPI users and 24.8% in nonusers 
[HR: 4.25 (95% CI: 1.42–12.67), P  =  0.05]. No signifi-
cant difference was found in patients who had a previous 
SBP episode (n  =  29) [55.7% vs. 50.0%, HR: 0.82 (95% 
CI: 0.23–2.93), P  =  NS].
Table 1. Clinical characteristics of patients with cirrhosis
Number
Total
350
Gender (male/female) 188/162
Age (years)a (median, IQR) 56 (50–64)
Alcoholic etiology 242 (69.1)
Child-Pugh stage, n (%)
 A 206 (58.9)
 B 108 (30.9)
 C 36 (10.3)
MELD scorea 11.5 (8–16)
Decompensated stage, n (%) 204 (58.3)
Comorbidity, n (%) 171 (48.9)
HCC, n (%) 33 (9.4)
Ascites, n (%) 113 (32.3)
Prior variceal bleeding, n (%) 100 (28.6)
Prior hepatic encephalopathy, n (%) 19 (5.4)
Prior SBP, n (%) 44 (12.6)
P values were calculated with Mann–Whitney U-test, χ2-test or Fisher’s exact 
test as appropriate.
HCC, hepatocellular carcinoma; IQR, inter quartile range; MELD: Model for 
end-stage liver disease score; NS: Nonsignificant; PPI, proton pump inhibitor; 
SBP, spontaneous bacterial peritonitis.
aMedian, IQR (lowest 25%–highest 25%).
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Advent of first decompensation event
Of patients with compensated clinical stage, 18.5% 
(27/146) experienced a decompensation event (ascites, 
variceal bleeding, or hepatic encephalopathy). The 
median time to the development of the first decompensa-
tion episode was 540  days [IQR, 189–900]. PPI use was 
associated with an increased cumulative probability of 
the development of the first decompensation event com-
pared with PPI nonuse (41.9%  ±  8.5 vs. 17.7%  ±  6.4 
with HR: 2.81, 95% CI: 1.31–6.01, P  =  0.008) (Table 4 
and Fig.  2). Sensitivity analysis according to the PPI 
dose showed that only long-standing double dose PPI 
therapy (HR: 6.63, 95% Cl: 2.7–16.3, P  <  0.001) and 
not the standard one (HR: 2.09, 95% Cl: 0.85–5.14, 
P  =  0.106) associated to higher risk of decompensation 
of the disease.
Covariates
Univariate Cox regression analysis of clinical factors asso-
ciated with the development of a decompensation event is 
shown in Table 4. Higher MELD score (HR: 1.21, 95% 
CI: 1.10–1.34, P  <  0.001) was significantly associated 
with the increased risk for the development of the first 
decompensation event.
Multivariate analysis
Cox regression analysis and the backward elimination 
procedure, taking the status of PPI use and MELD into 
account, indicated that PPI use, and higher MELD score 
were independently associated with the risk of the devel-
opment of first decompensating event (Table 4).
Mortality
In the total cohort, liver-related mortality occurred in 147 
(42.0%) patients. Kaplan–Meier survival analysis demon-
strated a significantly worse survival in patients with 
advanced disease, according to the presence of decom-
pensated clinical stage (P  <  0.001) or higher MELD score 
(P  <  0.001), age (P  =  0.026), comorbidity (P  =  0.007), 
Table 2. Clinical characteristics of patients with ascites at inclusion
Number
Total
113
PPI user
74
PPI nonuser
39 P value
Gender (male/female) 69/77 48/26 19/20 0.098
Age (years)a (median, IQR) 58 (52–65) 58 (52–65) 56 (52–66) 0.962
Alcoholic etiology 93 (82.3) 62 (83.8) 31 (79.5) 0.571
Child-Pugh stage, n (%)
 A 19 (16.8) 14 (18.9) 5 (12.8) 0.057
 B 61 (54.0) 34 (45.9) 27 (69.2)
 C 33 (29.2) 26 (35.1) 7 (17.9)
MELD scorea 15 (12–19) 16 (13–21) 14 (11–18) 0.055
Comorbidity, n (%) 57 (50.4) 42 (56.8) 15 (38.5) 0.066
HCC, n (%) 11 (9.7) 7 (9.5) 4 (10.3) 0.892
Prior variceal bleeding, n (%) 31 (27.4) 25 (33.8) 6 (15.4) 0.038
Prior hepatic encephalopathy, n (%) 11 (9.7) 11 (14.9) 0 (0.0) 0.012
Prior SBP, n (%) 28 (24.8) 22 (29.7) 6 (15.4) 0.095
P values were calculated with Mann–Whitney U-test, χ2-test or Fisher’s exact test as appropriate.
HCC, hepatocellular carcinoma; IQR, inter quartile range; MELD: Model for end-stage liver disease score; NS: Nonsignificant; PPI, proton pump inhibitor; SBP, 
spontaneous bacterial peritonitis.
aMedian, IQR (lowest 25%–highest 25%).
Table 3. Clinical characteristics of compensated patients with cirrhosis
Number
Total
146
PPI user
50
PPI nonuser
96 P value
Gender (male/female) 69/77 21/29 48/48 0.360
Age (years)a (median, IQR) 56 (49–64) 56.5 (49–64) 56 (51–64) 0.977
Alcoholic etiology 74 (50.7) 27 (54.0) 47 (49.0) 0.564
Child-Pugh stage, n (%)
 A 121 (82.9) 38 (76.0) 83 (86.59) 0.111
 B 25 (17.1) 12 (24.0) 12 (13.5)
 C    
MELD scorea 9 (7–13) 9 (7–13) 8 (7–11) 0.118
Comorbidity, n (%) 71 (48.6) 25 (50.0) 46 (47.9) 0.812
HCC, n (%) 17 (11.6) 4 (8.0) 13 (13.5) 0.324
P values were calculated with Mann–Whitney U-test, χ2-test or Fisher’s exact 
test as appropriate.
CC, hepatocellular carcinoma; IQR, inter quartile range; MELD, Model for end-
stage liver disease score; NS, Nonsignificant; PPI, proton pump inhibitor.
aMedian, IQR (lowest 25%–highest 25%)
Fig. 1. Development of spontaneous bacterial peritonitis in patients with-
out previous SBP episode according to PPI use. PPI use increased the risk 
of SBP development in those patients who had not got previous SBP epi-
sode. PPI, proton pump inhibitor; SBP, spontaneous bacterial peritonitis.
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and alcoholic etiology (P  =  0.005). Long-standing PPI use 
(P  <  0.001) was also associated with a lower survival rate 
(Table 5 and Fig. 3). PPI use (HR: 2.01, 95% CI: 1.38–
2.93, P  <  0.001), and clinical stage (HR: 1.66, 95% CI: 
1.12–2.45, P  =  0.011) and MELD score (HR: 1.12, 95% 
CI: 1.08–1.55, P  <  0.001) remained independent predic-
tors of mortality in multivariate analysis, as well (Table 5).
Further analyzing the mortality risk between groups of 
patients with different disease severity, we revealed that 
the PPI use was only associated with higher risk of mor-
tality in the compensated patient group (HR: 2.81, 95% 
Cl: 1.43–5.51, P  =  0.003), but not in the decompensated 
one (HR: 1.42, 95% Cl: 0.89–2.26, P  =  1.37). These find-
ings, however, were independent of PPI dosage in both the 
compensated (HR: 2.73, 95% Cl: 1.31–5.69, P  =  0.008 
and HR: 4.28, 95% Cl: 1.88–9.73, P  =  0.001) and decom-
pensated patient group (HR: 1.64, 95% Cl: 0.99–2.72, 
P  =  0.54 and HR: 1.58, 95% Cl: 0.95–2.63, P  =  0.81).
Discussion
Most previous clinical studies assessing the impact of PPI 
use in cirrhosis addressed patients with an advanced dis-
ease stage. None included patients with a compensated 
disease stage. These studies tell us primarily about the 
development of SBP in ascitic patients and very little about 
the long-term effects of PPI use or disease-specific compli-
cations beyond SBP among patients with cirrhosis [32]. 
This study addresses the gap in our knowledge by compre-
hensively assessing the significance of long-term PPI use in 
a large cohort of patients on the entire severity spectrum 
of cirrhosis, with special emphasis on the progressive dis-
ease course.
Previous studies [17–28] evaluating the impact of PPI 
use on SBP development have yielded inconsistent results. 
Most of the inconsistencies can be attributed to differ-
ences in study design, sample size, and inclusion criteria. 
Definitions of PPI use were often vague and did not spec-
ify the exact duration of PPI use. To address the possibil-
ity that the unfavorable effects of PPI use need time to 
develop, this study used a long follow-up time (median of 
1155 days). To ensure clarity of definition of PPI use, we 
followed rigorous criteria to divide subjects into PPI user 
and nonuser patient groups and excluded patients with 
episodic or uncertain PPI use.
In the present study, long-term PPI use was found to 
be significantly associated with increased risk of SBP 
development in patients with ascites, which is only one 
consequence of PPI-provoked bacterial translocation. 
According to the most widely accepted hypothesis for 
the association of PPI use and SBP, decreased gastric acid 
Fig. 2. Development of first decompensation event in patients with com-
pensated clinical stage according to PPI use. PPI use was associated with 
an increased cumulative probability of the development of first decompen-
sation event compared to PPI nonuse. PPI, proton pump inhibitor.
Table 4. Univariate and multivariate Cox-regression analysis for the association of proton pump inhibitor use and clinical factors with the cumula-
tive probability of decompensation patients with compensated clinical stage
Development of decompensation  Univariate analysis Mulivariate analysis
n of subjects n of events
Cumulative probability  
of event % P valuea HR (95% CI) P value HR (95% CI) P value
Compensated stage 146 27 25.6 –     
Age (years)
 <65 113 20 23.2      
 >65 33 7 35.2 0.398 1.48 (0.62–3.52) 0.376   
Gender
 Male 70 15 29.4      
 Female 76 12 21.8 0.304 1.49 (0.7–3.18) 0.306   
Comorbidity
 Absent 75 11 19.8      
 Present 71 16 32.3 0.162 1.69 (0.78–3.65) 0.18   
Etiology
 Other 71 8 18.9      
 Alcohol 75 19 31.8 0.042 2.30 (1.00–5.25) 0.049 1.55 (0.66–3.67) 0.31
MELD score (per 1 point increase)
 NA NA  NA  1.21 (1.10–1.34) <0.001 1.21 (1.08–1.35) 0.001
PPI use
 No 96 12 17.7      
 Yes 50 15 41.9 0.004 2.81 (1.31–6.01) 0.008 2.58 (1.20–5.55) 0.015
CI, confidence interval; HR, hazard ratio; NA, not applicable; PPI, proton pump inhibitor.
aP values were calculated by the log-rank test.
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production enhances the development of small intestinal 
bacterial overgrowth (SIBO). Gastric acid has a strong 
bactericidal effect, which can decontaminate the stomach 
and proximal small intestine. PPI therapy may interfere 
with this first line of immune defense against orally enter-
ing pathogens. PPI has also been shown to slow gastro-
intestinal motility [33], delay gastric emptying [34], and 
decrease gastric mucus viscosity [35], all of which might 
have direct effects on gut microflora and the survival of 
enteric pathogens that may lead to SIBO. Some of the 
studies could not confirm the more common SIBO in PPI 
users [36], but the above-mentioned PPI effects and the 
fact that SIBO is commonly developed in the absence of 
gastric acid after a total gastrectomy [37] support this the-
ory. A recent subgroup meta-analysis of recently published 
large-scale meta-analysis unequivocally supports this idea 
[38]. Studies that employed either a direct test (culture of 
small bowel aspirates) or an indirect test of SIBO (glucose 
hydrogen breath tests) were included in the meta-analy-
sis. Direct tests confirmed the association between PPI use 
and SIBO [39], indirect tests could not [36]. The analysis 
concluded that use of PPI moderately increases the risk of 
SIBO with the pooled odds ratio of 1.71 (95% CI: 1.20–
2.43) [38].
We must suppose that SIBO is not the only factor that 
provokes SBP. PPI therapy does not only provoke SIBO 
but it can also have other undesirable effects, for example, 
it can alter the composition and function of the intestinal 
microflora [40]. Interestingly, Wallace et al. [41] reported 
that PPI might exacerbate nonsteroidal anti-inflammatory 
drug-induced small bowel injury, which they explained as 
a consequence of dysbiosis.
In addition to its acid-suppressive effect, PPI can also 
weaken the innate immune response by impairing neutro-
phil function. As appropriate H+-pump activity is neces-
sary for the rapid release of toxic reactive oxygen species 
and interleukin-8 production, inhibition of the H+-pump 
due to acid suppression can decrease both the function 
and recruitment of inflammatory cells reducing bacteri-
cidal activity [42]. These mechanisms elucidate the role of 
PPI in the development of pneumonia and other serious 
healthcare-associated and hospital-acquired infections 
[43]. SIBO, dysbiosis, and altered immune function all 
enhance bacterial translocation.
As PPI is considered to be well tolerated, its dose is 
usually not adjusted to liver function. It is known that the 
half-life of PPI is increased in patients with impaired liver 
function. As a result, prolonged high serum concentration 
of the drug potentiates acid suppression and may increase 
Fig. 3. Liver-related mortality according to PPI use. PPI use (P  <  0.001) is 
associated with worse survival. PPI, proton pump inhibitor.
Table 5. Univariate and multivariate Cox-regression analysis for the association of proton pump inhibitor use and clinical factors with the liver-re-
lated mortality
Mortality event  Univariate analysis Mulivariate analysis
n of subjects n of events
Cumulative probability  
of event % P valuea HR (95% CI) P value HR (95% CI) P value
Total cohort 350 147 42 -     
Age (years)
 <65 296 104 53.2      
 >65 81 43 79.2 0.026 1.49 (1.05–2.13) 0.027 1.40 (0.98–2.01) 0.069
Gender
 Male 188 80 57.8      
 Female 162 67 61.4 0.647 0.93 (0.67–1.28) 0.647   
Comorbidity
 Absent 171 59 50.3      
 Present 179 88 68.2 0.007 1.57 (1.13–2.18) 0.008 1.32 (0.93–1.85) 0.152
Etiology
 Other 108 31 39.6      
 Alcohol 242 116 67.5 0.005 1.76 (1.18–2.62) 0.005 1.12 (0.729–1.726) 0.6
MELD score (per 1 point increase)    <0.001 1.14 (1.1–1.17) <0.001 1.12 (1.08–1.55) <0.001
Clinical stage
 Comp. 163 46 42.8      
 Decomp. 187 101 71.6 <0.001 2.52 (1.78–3.58) <0.001 1.66 (1.12–2.45) 0.011
PPI use
 No 154 39 33.9      
 Yes 196 108 75.1 <0.001 2.63 (1.82–3.79) <0.001 2.01 (1.38–2.93) <0.001
CI, confidence interval; Comp, clinically compensated disease stage; Decomp, clinically decompensated disease stage; HR, hazard ratio; PPI, proton pump 
inhibitor.
aP values were calculated by the log-rank test.
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PPI associated side effects [44]. Immune suppressive effects 
can be more harmful in patients with cirrhosis known to 
be immunocompromised with a multifactorial state of 
systemic immune dysfunction [45]. The unnecessarily high 
dose of the drug further enhances negative effects of PPI.
We found, for the first time, that PPI use increased the 
risk of SBP development only for patients who did not 
have a previous SBP episode. Initiation of antibiotic treat-
ment as a secondary prophylaxis might counteract the 
enhanced bacterial translocation induced by PPI treat-
ment, and so make subsequent episodes less likely.
Habits of PPI use in cirrhosis show that the drug is 
more commonly prescribed for patients with advanced 
disease stage [32] that was also found in our study. 
Abdominal discomfort is frequent in this stage of the dis-
ease due to the accumulation of large volume of ascites 
that can be mistakenly treated with PPI. Increased fre-
quency of gastroesophageal reflux in this population is a 
matter of debate.
Pathological bacterial translocation is associated with 
clinically relevant complications in cirrhosis beyond SBP 
[46].
Our study is the first to consider the effect of long-term 
PPI use on the development of a range of bacterial translo-
cation-related diseases. We hypothesized that if long-term 
PPI use was linked to bacterial translocation, it would be 
associated with enhanced disease progression, for exam-
ple, the appearance of the first decompensation event or 
liver-related death. Our results confirmed this hypothesis 
and are in accord with the recent finding of Llorente et al. 
[47] that PPI use increased the risk of alcohol-dependent 
patients developing alcoholic liver disease. They proposed 
a background mechanism based on data from mouse mod-
els in which gastric acid suppression increases intestinal 
overgrowth of Enterococcus. Translocation of this type 
of gut bacteria into the liver via the portal vein results in 
the binding of Enterococcus to the toll-like receptor 2 of 
hepatic Kupffer cells and secretion of IL1B. IL1B contrib-
utes to ethanol-induced liver inflammation and hepatocyte 
damage.
The worst outcome, mortality, was also evaluated. The 
effect of PPI on mortality has been assessed in only one 
previous study [32]. It found that PPI use was an inde-
pendent predictor of mortality (HR: 2.330 [95% CI, 
1.264–4.296], P  =  0.007). We also found an increased 
hazard of death related to PPI use (HR: 2.01 [95% CI, 
1.38–2.93], P  <  0.001).
In summary, we were able to confirm previous findings 
that long-term PPI use increased the risk of SBP, and we 
found that PPI use was associated with the development 
of clinical decompensation and liver-related death during 
 follow-up. These results support our hypothesis that SBP is 
only one consequence of enhanced bacterial translocation 
provoked by PPIs, which warrants a cautious approach to 
prescribe PPIs to patients with cirrhosis.
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